Here are four things to know.
- Neulasta, which earned about $4.6 billion in sales last year, is used to treat infections in cancer patients.
- The biosimilar represents one of Coherus’ lead experimental drugs, according to Reuters.
- Upon notification of the rejection, the FDA asked the drugmaker to reanalyze data and provide additional manufacturing information, according to the report.
- Coherus said it plans to work with the agency to address its concerns.
More articles on supply chain:
Bristol-Myers susceptible to acquisition following failed cancer trial, investors say
FDA approves Qiagen’s TB blood test: 3 things to know
7% of cancer patients say pharma prices drugs fairly: 5 survey findings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.